Insulin-resistance and benign prostatic hyperplasia: The connection

European Journal of Pharmacology

Volumn 641, Issue 2-3, 2010, Pages 75-81

  Vikram, Ajit ^a   Jena, Gopabandhu ^a   Ramarao, Poduri ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

BPH; Diabetes; Hyperinsulinemia; Hyperplasia; Insulin resistance; Obesity; Prostate

Indexed keywords

ANDROGEN; ANDROSTANOLONE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; I KAPPA B KINASE; INSULIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; SOMATOMEDIN; TESTOSTERONE;

BODY MASS; DYSLIPIDEMIA; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; NONHUMAN; OBESITY; OVERACTIVE BLADDER; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; WAIST HIP RATIO; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ANIMALS; DYSLIPIDEMIAS; HUMANS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PROSTATE; PROSTATIC HYPERPLASIA; RATS; RISK FACTORS;

EID: 77954085409     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.05.042     Document Type: Review

References (85)

1. Banerjee P.P., Banerjee S., Lai J.M., Strandberg J.D., Zirkin B.R., Brown T.R. Age-dependent and lobe-specific spontaneous hyperplasia in the brown Norway rat prostate. Biol. Reprod. 1998, 59:1163-1170.
2. Barnard R.J., Aronson W.J. Benign prostatic hyperplasia: does lifestyle play a role?. Phys. Sportsmed. 2009, 37:141-146.
3. Becker S., Dossus L., Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch. Physiol. Biochem. 2009, 115:86-96.
4. Belfiore A., Frasca F. IGF and insulin receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13:381-406.
5. Berry S.J., Coffey D.S., Walsh P.C., Ewing L.L. The development of human benign prostatic hyperplasia with age. J. Urol. 1984, 132:474-479.
6. Bosch R.J. Pathogenesis of benign prostatic hyperplasia. Eur. Urol. 1991, 20:27-30.
7. Bravi F., Bosetti C., Dal Maso L., Talamini R., Montella M., Negri E., Ramazzotti V., Franceschi S., La Vecchia C. Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia. Urology 2006, 67:1205-1211.
8. Cai X., Haleem R., Oram S., Cyriac J., Jiang F., Grayhack J.T., Kozlowski J.M., Wang Z. High fat diet increases the weight of rat ventral prostate. Prostate 2001, 49:1-8.
9. Cai J.L., Xin D.Q., He Q., Tang X.Q., Na Y.Q. Pathological changes of benign hyperplastic prostate after removal of innervation of cholinergic pelvic nerve: experiment with spontaneous hypertension rats. Zhonghua Yi Xue Za Zhi 2008, 88:1284-1288.
10. Catenacci V.A., Hill J.O., Wyatt H.R. The obesity epidemic. Clin. Chest Med. 2009, 30:415-444.
11. Chokkalingam A.P., Gao Y.T., Deng J., Stanczyk F.Z., Sesterhenn I.A., Mostofi F.K., Fraumeni J.F., Hsing A.W. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 2002, 52:98-105.
12. Cohick W.S., Clemmons D.R. The insulin-like growth factors. Annu. Rev. Physiol. 1993, 55:131-153.
13. Cohn G., Valdes G., Capuzzi D.M. Pathophysiology and treatment of the dyslipidemia of insulin resistance. Curr. Cardiol. Rep. 2001, 3:416-423.
14. Dahle S.E., Chokkalingam A.P., Gao Y.T., Deng J., Stanczyk F.Z., Hsing A.W. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J. Urol. 2002, 168:599-604.
15. de Voogt H.J., Rao B.R., Geldof A.A., Gooren L.J., Bouman F.G. Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate. Prostate 1987, 11:305-311.
16. Doggweiler R., Zermann D.H., Ishigooka M., Schmidt R.A. Botox-induced prostatic involution. Prostate 1998, 37:44-50.
17. Ehrmann D.A. Insulin-lowering therapeutic modalities for polycystic ovary syndrome. Endocrinol. Metab. Clin. N. Am. 1999, 28:423-438.
18. Engelstein D., Shmueli J., Bruhis S., Servadio C., Abramovici A. Citral and testosterone interactions in inducing benign and atypical prostatic hyperplasia in rats. Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol. 1996, 115:169-177.
19. Escobar E.L., Gomes-Marcondes M.C., Carvalho H.F. Dietary fatty acid quality affects AR and PPARgamma levels and prostate growth. Prostate 2009, 69:548-558.
20. Fan W., Yanase T., Morinaga H., Okabe T., Nomura M., Daitoku H., Fukamizu A., Kato S., Takayanagi R., Nawata H. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J. Biol. Chem. 2007, 282:7329-7338.
21. Frayn K. Insulin resistance and lipid metabolism. Curr. Opin. Lipidol. 1993, 4:197-204.
22. Giovannucci E., Rimm E.B., Chute C.G., Kawachi I., Colditz G.A., Stampfer M.J., Willett W.C. Obesity and benign prostatic hyperplasia. Am. J. Epidemiol. 1994, 140:989-1002.
23. Golomb E., Kruglikova A., Dvir D., Parnes N., Abramovici A. Induction of atypical prostatic hyperplasia in rats by sympathomimetic stimulation. Prostate 1998, 34:214-221.
24. Golomb E., Rosenzweig N., Eilam R., Abramovici A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J. Androl. 2000, 21:58-64.
25. Gupta A., Gupta S., Pavuk M., Roehrborn C.G. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 2006, 68:1198-1205.
26. Hammarsten J., Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999, 8:29-36.
27. Hammarsten J., Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur. Urol. 2001, 39:151-158.
28. Hammarsten J., Hogstedt B., Holthuis N., Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998, 1:157-162.
29. Hammarsten J., Damber J.E., Karlsson M., Knutson T., Ljunggren O., Ohlsson C., Peeker R., Smith U., Mellstrom D. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2009, 12:160-165.
30. Ikeda K., Wada Y., Foster H.E., Wang Z., Weiss R.M., Latifpour J. Experimental diabetes-induced regression of the rat prostate is associated with an increased expression of transforming growth factor-beta. J. Urol. 2000, 164:180-185.
31. Issa M.M., Regan T.S. Medical therapy for benign prostatic hyperplasia-present and future impact. Am. J. Manage. Care 2007, 13:S4-S9.
32. Karatas, O.F., Bayrak, O., Cimentepe, E., Unal, D., in press. An insidious risk factor for cardiovascular disease: Benign prostatic hyperplasia. Int. J. Cardiol. PMID: 19359054.
33. Kasturi S., Russell S., McVary K.T. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr. Urol. Rep. 2006, 7:288-292.
34. Kayampilly P.P., Wanamaker B.L., Menon K.M. Evidence that insulin stimulates 5alpha-reductase (Type 1) mRNA and protein expression in ovarian granulosa cells: a possible mechanism of ovulatory dysfunction under hyperinsulinaemic state. Biol. Reprod. 2009, 81:563.
35. Kim J.A., Montagnani M., Koh K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
36. Kogai M.A., Lutov U.V., Selyatitskaya V.G. Hormonal and biochemical parameters of metabolic syndrome in male patients with body weight excess and obesity. Bull. Exp. Biol. Med. 2008, 146:806-808.
37. Kovacs P., Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract. Res. Clin. Endocrinol. Metab. 2005, 19:625-635.
38. Kristal A.R., Arnold K.B., Schenk J.M., Neuhouser M.L., Weiss N., Goodman P., Antvelink C.M., Penson D.F., Thompson I.M. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J. Urol. 2007, 177:1395-1400.
39. Lee S.H., Kim J.C., Lee J.Y., Kim J.H., Oh C.Y., Lee S.W., Yoo S.J., Chung B.H. Effects of obesity on lower urinary tract symptoms in Korean BPH patients. Asian J. Androl. 2009, 11:663-668.
40. Li G., Barrett E.J., Wang H., Chai W., Liu Z. Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. Endocrinology 2005, 146:4690-4696.
41. Li P.J., Zhang X.H., Guo L.J., Na Y.Q. Correlation of benign prostatic hyperplasia with hyperlipemia. Zhonghua Wai Ke Za Zhi 2005, 43:387-389.
42. Lucia M.S., Lambert J.R. Growth factors in benign prostatic hyperplasia: basic science implications. Curr. Urol. Rep. 2008, 9:272-278.
43. Marker P.C., Donjacour A.A., Dahiya R., Cunha G.R. Hormonal, cellular, and molecular control of prostatic development. Dev. Biol. 2003, 253:165-174.
44. Matityahou A., Rosenzweig N., Golomb E. Rapid proliferation of prostatic epithelial cells in spontaneously hypertensive rats: a model of spontaneous hypertension and prostate hyperplasia. J. Androl. 2003, 24:263-269.
45. McKeehan W.L., Adams P.S., Rosser M.P. Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res. 1984, 44:1998-2010.
46. McVary K.T., Rademaker A., Lloyd G.L., Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 2005, 174:1327-1433.
47. Meigs J.B., Mohr B., Barry M.J., Collins M.M., McKinlay J.B. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J. Clin. Epidemiol. 2001, 54:935-944.
48. Montagnani M., Golovchenko I., Kim I., Koh G.Y., Goalstone M.L., Mundhekar A.N., Johansen M., Kucik D.F., Quon M.J., Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J. Biol. Chem. 2002, 277:1794-1799.
49. Morales C.R., Badran H. Prosaposin ablation inactivates the MAPK and Akt signaling pathways and interferes with the development of the prostate gland. Asian J. Androl. 2003, 5:57-63.
50. Nam S.Y., Lee E.J., Kim K.R., Cha B.S., Song Y.D., Lim S.K., Lee H.C., Huh K.B. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int. J. Obes. Relat. Metab. Disord. 1997, 21:355-359.
51. Nandeesha H. Benign prostatic hyperplasia: dietary and metabolic risk factors. Int. Urol. Nephrol. 2008, 40:649-656.
52. Nandeesha H., Koner B.C., Dorairajan L.N., Sen S.K. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin. Chim. Acta 2006, 370:89-93.
53. Noa M., Arruzazabala M.L., Carbajal D., Mas R., Molina V. Effect of D-004, a lipid extract from Cuban royal palm fruit, on histological changes of prostate hyperplasia induced with testosterone in rats. Int. J. Tissue React. 2005, 27:203-211.
54. Ozden C., Ozdal O.L., Urgancioglu G., Koyuncu H., Gokkaya S., Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur. Urol. 2007, 51:199-203.
55. Palatini P. Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease. Curr. Hypertens. Rep. 2001, 3:S3-S9.
56. Park H.K., Lee H.W., Lee K.S., Byun S.S., Jeong S.J., Hong S.K., Lee S.E., Park J.H., Lee S.B., Kim K.W. Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population. Urology 2008, 72:556-560.
57. Parsons J.K., Carter H.B., Partin A.W., Windham B.G., Metter E.J., Ferrucci L., Landis P., Platz E.A. Metabolic factors associated with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 2006, 91:2562-2568.
58. Parsons J.K., Bergstrom J., Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int. 2008, 101:313-318.
59. Parsons J.K., Sarma A.V., McVary K., Wei J.T. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J. Urol. 2009, 182:S27-S31.
60. Peehl D.M., Cohen P., Rosenfeld R.G. The insulin-like growth factor system in the prostate. World J. Urol. 1995, 13:306-311.
61. Rahman N.U., Phonsombat S., Bochinski D., Carrion R.E., Nunes L., Lue T.F. An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat. BJU Int. 2007, 100:658-663.
62. Riccardi G., Giacco R., Rivellese A.A. Dietary fat, insulin sensitivity and the metabolic syndrome. Clin. Nutr. 2004, 23:447-456.
63. Sanda M.G., Beaty T.H., Stutzman R.E., Childs B., Walsh P.C. Genetic susceptibility of benign prostatic hyperplasia. J. Urol. 1994, 152:115-119.
64. Sarma A.V., Kellogg Parsons J. Diabetes and benign prostatic hyperplasia: emerging clinical connections. Curr. Urol. Rep. 2009, 10:267-275.
65. Servadio C., Abramovici A., Sandbank U., Savion M., Rosen M. Early stages of the pathogenesis of rat ventral prostate hyperplasia induced by citral. Eur. Urol. 1986, 12:195-200.
66. Shabsigh A., Chang D.T., Heitjan D.F., Kiss A., Olsson C.A., Puchner P.J., Buttyan R. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998, 36:201-206.
67. Shulman G.I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 2000, 106:171-176.
68. Silva J., Pinto R., Carvallho T., Coelho A., Avelino A., Dinis P., Cruz F. Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat. Eur. Urol. 2009, 56:134-140.
69. Srinivasan G., Campbell E., Bashirelahi N. Androgen, estrogen, and progesterone receptors in normal and aging prostates. Microsc. Res. Tech. 1995, 30:293-304.
70. Stamatiou K., Lardas M., Kostakos E., Koutsonasios V., Michail E. The impact of diabetes type 2 in the pathogenesis of benign prostatic hyperplasia: a review. Adv. Urol. 2009, 818965. PMID: 19902013.
71. Taniguchi C.M., Emanuelli B., Kahn C.R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 2006, 7:85-96.
72. Thiyagarajan M., Kaul C.L., Ramarao P. Enhancement of alpha-adrenoceptor-mediated responses in prostate of testosterone-treated rat. Eur. J. Pharmacol. 2002, 453:335-344.
73. Thor P.J., Mazur M., Furgala A., Worek M. The autonomic nervous system function in benign prostatic hyperplasia. Folia Med. Cracov. 2006, 47:79-86.
74. Ullrich A., Gray A., Tam A.W., Yang-Feng T., Tsubokawa M., Collins C., Henzel W., Le Bon T., Kathuria S., Chen E., et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986, 5:2503-2512.
75. Vikram A., Tripathi D.N., Ramarao P., Jena G.B. Intervention of d-glucose ameliorates the toxicity of streptozotocin in accessory sex organs of rat. Toxicol. Appl. Pharmacol. 2008, 226:84-93.
76. Vikram A., Jena G.B., Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate 2010, 70:79-89.
77. Vogeser M., Schwandt P., Haas G.M., Broedl U.C., Lehrke M., Parhofer K.G. BMI and hyperinsulinemia in children. Clin. Biochem. 2009, 42:1427-1430.
78. Wadsworth T.L., Carroll J.M., Mallinson R.A., Roberts C.T., Roselli C.E. Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology 2004, 145:3205-3214.
79. Ward K.D., Sparrow D., Landsberg L., Young J.B., Vokonas P.S., Weiss S.T. Influence of insulin, sympathetic nervous system activity, and obesity on blood pressure: the Normative Aging Study. J. Hypertens. 1996, 14:301-308.
80. Wertz K., Siler U., Goralczyk R. Lycopene: modes of action to promote prostate health. Arch. Biochem. Biophys. 2004, 430:127-134.
81. Yang M.G., Zhao X.K. Progress in the studies of alpha1-adrenoceptor blocker for concurrent benign prostatic hyperplasia and hypertension. Zhonghua Nan Ke Xue 2007, 13:830-834.
82. Yono M., Pouresmail M., Takahashi W., Flanagan J.F., Weiss R.M., Latifpour J. Effect of insulin treatment on tissue size of the genitourinary tract in BB rats with spontaneously developed and streptozotocin-induced diabetes. Naunyn Schmiedebergs Arch. Pharmacol. 2005, 372:251-255.
83. Yono M., Mane S.M., Lin A., Weiss R.M., Latifpour J. Differential effects of diabetes induced by streptozotocin and that develops spontaneously on prostate growth in Bio Breeding (BB) rats. Life Sci. 2008, 83:192-197.
84. Yu C., Chen Y., Cline G.W., Zhang D., Zong H., Wang Y., Bergeron R., Kim J.K., Cushman S.W., Cooney G.J., Atcheson B., White M.F., Kraegen E.W., Shulman G.I. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 2002, 277:50230-50236.
85. Zucchetto A., Tavani A., Dal Maso L., Gallus S., Negri E., Talamini R., Franceschi S., Montella M., La Vecchia C. History of weight and obesity through life and risk of benign prostatic hyperplasia. Int. J. Obes. 2005, 29:798-803.